Interestingly, a more recent report identified Pacritinib as being effective in AML mouse models and patient samples irrespective of the mutational status of FLT3 and JAK2. The therapeutic effect was attributed to efficient IRAK1 inhibition rendering this kinase a novel target in AML [138]. This evidence concerns the gene FLT3 and acute myeloid leukemia.